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Abstract
Akt is a serine threonine kinase with a major role in transducing survival signals and regulating proteins involved in apoptosis.
To find new interactors of Akt involved in cell survival, we performed a two-hybrid screening in yeast using human full-length
Akt c-DNA as bait and a murine c-DNA library as prey. Among the 80 clones obtained, two were identified as Bcl-w. Bcl-w is a
member of the Bcl-2 family that is essential for the regulation of cellular survival, and that is up-regulated in different human
tumors, such as gastric and colorectal carcinomas. Direct interaction of Bcl-w with Akt was confirmed by immunoprecipitation
assays. Subsequently, we addressed the function of this interaction: by interfering with the activity or amount of Akt, we have
demonstrated that Akt modulates the amount of Bcl-w protein. We have found that inhibition of Akt activity may promote
apoptosis through the downregulation of Bcl-w protein and the consequential reduction in interaction of Bcl-w with pro-
apoptoticmembersoftheBcl-2 family. Our dataprovide evidencethatBcl-wisa new memberofthe Aktpathwayand thatAkt
may induce anti-apoptotic signals at least in part through the regulation of the amount and activity of Bcl-w.
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Introduction
Akt is a serine–threonine kinase downstream of PTEN/PI3K,
involved in cellular survival pathways [1,2]. In mammalian cells, the
three Akt family members, Akt1/PKBa, Akt2/PKBb,a n dA k t 3 /
PKBc are encoded by three different genes [3,4]. They are
ubiquitously expressed, although their levels are variable, depending
upon the tissue type and pathological/physiological state. Increased
expression or activation of Akt has been described as a frequent
phenomena in human cancer [1,5,6]. Akt has been demonstrated to
phosphorylate a number of proteins involved in apoptotic signaling
cascades, including the Bcl-2 family member BAD [7], pro-caspase 9
[4], the forkhead transcription factors, FKHR and FKHRL1 [8,9],
and p21 cipWAF1. Phosphorylation of these proteins prevents
apoptosis through several mechanisms [10]. Apoptosis, or pro-
grammed cell death, is an evolutionarily conserved mechanism of
elimination of unwanted cells [11]. Apoptosis is triggered via two
principal signaling pathways [12]. The extrinsic pathway is activated
by the engagement of death receptors on the cell surface [13]. The
other pathway is triggered by various intracellular and extracellular
stresses, such as growth–factor wit h d r a w a l ,h y p o x i a ,D N Ad a m a g e ,
and anticancer therapy [13,14]. Intrinsic-pathway induced-apoptosis
is generally regulated by the fine balance of Bcl-2 family proteins in a
cell- and tissue-specific manner [11]. Apoptosis is believed to be the
major mechanism responsible for chemotherapy-induced cell death
in cancer. However, tumor cells often retain the ability to evade drug-
induced death signals because of the activation of anti-apoptotic
mechanisms [15–17]. Understanding these evading mechanisms is a
first step needed for the design of rational anticancer therapy.
Therefore, we decided to address the role of Akt in apoptosis
resistance in human cancer by finding new partners involved in
resistance to cell death. To this end, we performed a two hybrid
screening in yeast using human full-length Akt c-DNA as bait and a
murine c-DNA library as prey. Among the possibleinteractors of Akt,
we decided to focus on Bcl-w, a member of the Bcl-2 family.
Biochemical experiments confirmed the interaction of Akt with Bcl-
w. Further, we demonstrate that Akt modulates the half-life of Bcl-w.
We also found that Bcl-w is a substrate of Akt and, more importantly,
that Akt regulates its anti-apoptotic activity and interaction with some
of the pro-apoptotic members of the Bcl-2 family.
Methods
Materials
Media, sera, and antibiotics for cell culture were from Life
Technologies, Inc. (Grand Island, NY, USA). Protein electropho-
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Western blotting and ECL reagents were from GE Healthcare. All
other chemicals were from Sigma (St. Louis, MO, USA).
Plasmids
Plasmids pEF FLAG(hs) Bcl-w , pEF EE Bax, pEF EE Bik, pEF
EE Bad cDNAs were kindly provided by Elisabeth Cory and
David Huang laboratories (Victoria, Australia). Akt wild type (HA-
Akt, cDNA), Akt E40 K (constitutively active Akt cDNA, HA-Akt-
D+) and Akt K179M (dominant negative Akt cDNA, HA-Akt-D-)
were a kind gift of Prof. G.L. Condorelli (University of Rome ‘‘La
Sapienza’’).
Cell culture
Human HeLa and HEK-293 cell lines were grown in DMEM
containing 10% heat-inactivated FBS and with 2 mM L-glutamine
and 100 U/ml penicillin-streptomycin.
Yeast Two-hybrid System
All experiments were performed in the yeast reporter MaV203.
The cDNA library was synthesized from rat FRTL-5 cell poly(A)
+
RNA plasmid by Life Technologies and cloned into the
pPC86GAL4AD vector, and was kindly provided by Prof.
Roberto Di Lauro (Naples, Italy). Screening of the library was
performed essentially following instructions for the ProQuest two-
hybrid system (Life Technologies) and has been previously
described [18]. The GAL4 DNA-binding domain/hAkt fusion
was obtained from Dr. Alfonso Bellacosa (Fox Chase Cancer
Centre, Philadelphia, Pennsylvania, USA). Subsequently, yeast
pLEx4-Akt plasmid was transformed with the pPC86AD-cDNA
library and plated onto plates lacking histidine in the presence of
3AT (aminotriazole; 10 mM). Approximately 1.2610
6 individual
clones were plated, and about 200 grew on the selective medium.
Resistant colonies were grown on a master plate and then replica-
plated onto selection plates to determine their ability to induce
three independent reporters (HIS3, URA3, and lacZ). Eighty
independent clones were isolated after this first screening. DNA
was isolated from each positive clone and sequenced to identify the
inserts. Independent pPC86AD clones were retransformed into
yeast and tested for interaction with a fresh Akt clone.
Generation of Bcl-w deletion mutants
We generated by PCR two deletion mutants of Bcl-w cDNA,
using as template the plasmid pEF FLAG Bcl-w: the following
primers were used for the bclw-BH4 mutant, which included only
the N-terminal BH4 domain (45 aa): BH4-For-HINDIII:cccaagct-
tatggactacaaagacgatgacgataaag and BH4-Rev-Xba1: gctcta-
gaggcttggtgcagcgggtc; the following primers were used for CT-
Bcl-w, which included the remaining coding sequence of 97aa:
CT-For-HINDIII: cccaagcttcccagcagctgacccgct and CT-Rev-
Xba1: gctctagatcacttgctagcaaaaaaggccc.
Temperature cycles were the following: 95uC 1 minute; 95uC
50 seconds, 60uC 50 seconds, 68uC 7 minutes for 35 cycles; 68uC
2 minutes. The amplified sequences were cloned in p3X-Flag-
CMV previously linearized with the restriction enzymes HINDIII
and XbaI.
Generation of stable transfectants
HeLa cells were transfected with 4 mg of Flag-Bcl-w cDNA
using lipofectamine 2000 according to the manufacturer’s protocol
(InVitrogen, Carlsbad, CA). After 48 hr of transfection, cells were
selected using a medium containing 10% FBS, 2 mMol L-
glutammine, 100 U/ml pen/strep, and 3.75 mg/ml of puromicine.
After 15 days the clones were isolated and maintained in culture
with 2.5 mg/ml of puromicine. Twenty colonies were isolated and
tested through western blot to verify the expression of the
construct.
Western blotting
Total protein from HeLa and HEK 293 cells was extracted with
RIPA buffer (0.15 mM NaCl, 0.05 mM Tris-HCl, pH 7.5, 1%
Triton, 0.1% SDS, 0.1% sodium deoxycolate and 1% Nonidet
P40). Fifty mg of sample extract were resolved on 7.5–12% SDS-
polyacrylamide gels using a mini-gel apparatus (Bio-Rad Labora-
tories, Richmond, CA) and transferred to Hybond-C extra
nitrocellulose. Membranes were blocked for 1 hr with 5% non-fat
dry milk in TBS containing 0.05% Tween-20, incubated over night
with primary antibody, washed and incubated with secondary
antibody, and visualized by chemiluminescence. The following
primary antibodies were used: Anti Flag M2 and anti-b-actin
antibody from Sigma (St. Louis, MO, USA), anti HA and anti EE
from Covance (Berkeley,CA USA); anti Bcl-w from Abcam
(Cambridge, MA); anti-Akt, -Phospho Akt substrate, -phospho
ser473 Akt from Cell signalling (Danvers, MA USA); anti-Bcl2, -
BAD, -BIK and -BAX from Santa Cruz, Inc (Santa Cruz, CA
USA), caspase -9 and -3 from Cell Signaling (Danvers, MA USA),
and PARP antibodies from Santa Cruz (Santa Cruz, CA USA).
Phosphorylation experiments
In order to study Bcl-w phosphorylation in intact cells, 293 cells
were transiently transfected with different Akt cDNAs constructs
as indicated. After 24 h, the cells were rinsed with 150 mM NaCl
and incubated in serum-free culture medium for 16 h at 37uC.
Insulin (final concentration, 100 nM) or 20% serum was then
added, and the cells were rapidly rinsed with ice-cold saline
followed by solubilization with 0.5 ml of RIPA buffer per dish for
1h ra t4 uC. Lysates were centrifuged at 5,0006g for 20 min, and
solubilized proteins were precipitated with the indicated antibod-
ies, separated by SDS-PAGE, and revealed by western blot with
the anti-Akt substrate antibody that recognizes all the phosphor-
ylated Akt substrates (Cell Signaling, Danvers, MA USA).
Phospho-(Ser/Thr) Akt Substrate Antibody preferentially recog-
nizes peptides and proteins containing phospho-Ser/Thr preceded
by Lys/Arg at positions 25 and 23. Some cross-reactivity has
been described for peptides that contain phospho-Ser/Thr
preceded by Arg/Lys at positions 23 and 22, thus recognizing
also a low-stringency Akt kinase motif.
Immunoprecipitation
Cells were cultured at a final concentration of 90% in p100
plates. The cells were harvested with RIPA Buffer on a shaker for
30 minutes. 1 mg of total extract was immunoprecipitated using
the indicated antibodies (5 mg/ml Anti-FLAG, 2 mg/ml Anti-HA,
3 mg/ml anti-Akt, 5 mg/ml anti-Bcl-w, 3 mg/ml anti-EE), for
16 hrs on shaker. Then, A/G beads (Santa Cruz, Santa Cruz, CA
USA) were added for two hrs. The beads were washed for three
times with washing buffer (50 mM Tris Hcl pH 7.5, 150 mM
NaCl, 0.1% Triton, 10% glycerol), and then 20 ml of sample
buffer was added; the samples were boiled at 100uC for 5 minutes
and then the supernatants resolved by SDS-PAGE.
Cytosol/mitochondria separation
Cells were grown in p100 plates and the mitochondrial and
cytoplasmic fractions isolated using the Mitochondria/Cytosol
Fractionation Kit (Biovision San Francisco, CA USA) according to
the manufacturer’s protocol.
AKT and Cell Death
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Akt activity was assayed in vitro as previously reported [19].
Briefly, HEK-293 cells were transfected with 4 mg of Flag-Bcl-w
cDNA. 1 mg of total cell extract was immunoprecipitated using an
anti-FLAG antibody (Sigma) and A/G beads (SantaCruz, Santa
Cruz, CA USA) for 18 hr. The beads were incubated in a kinase
reaction mixture containing 20 mM HEPES [pH 7.2], 1 mM
MgCl2, 10 mM MnCl2,1 mM dithiothreitol, 5 mM ATP, 0.2 mM
EGTA, 1 mM protein kinase inhibitor, 10 mCi of [c–
32P]ATP,
and 2 mg of rAkt (Cell signaling, Danvers, MA USA) for
30 minutes at room temperature. The samples were boiled at
100uC for 5 minutes, centrifuged and the supernatant loaded on a
12.5% maxi protean gel (BioRad, Richmond VA, USA). The gel
was run overnight and then visualized by autoradiography.
Cell death and cell proliferation quantification
Cells were plated in 96-well plates in triplicate and incubated at
37uC in a 5%CO2 incubator. Different chemotherapics (30 mg/
ml cisplatin, 10 mg/ml epirubicin) were added for 24 hrs to the
medium. Cell viability was evaluated with the CellTiter 96H
Aqueous One Solution Cell Proliferation Assay (Promega,
Madison, WI), according to the manufacturer’s protocol. Meta-
bolically active cells were detected by adding 20 ml of MTT to
each well. After 2 h of incubation, the plates were analyzed in a
Multilabel Counter (Bio-Rad, Richmond, VA, USA). Apoptosis
was assessed using PI (propidium iodide)-FITC staining followed
by flow cytometric analysis. Cells were seeded at 1.8610
6 cells per
100 mm dish, grown overnight in 10% FBS/DMEM, washed with
PBS, then treated for 24 hours with chemotherapics. Following
incubation, cells were washed with cold PBS and removed from
the plates by mild trypsinization. The resuspended cells were
washed with cold PBS and stained with PI-FITC staining
according to the instructions provided by the manufacturer
(Roche Applied Science, Indianapolis, IN). Cells (50,000 per
sample) were then subjected to flow cytometric analysis. Flow
cytometry analysis were done as described [20]. The percentage of
apoptosis indicated was corrected for background levels found in
the corresponding untreated controls.
siRNA transfection
HeLa cells were cultured to 80% confluence and transiently
transfected using LIPOFECTAMINE 2000 with 100 nM anti-Akt
Figure 1. Akt interacts with Bcl-w. (A) Co-immunoprecipitation of endogenous Akt with Bcl-w. Wt HeLa cells were lysed and 1 mg of protein
extract immunoprecipitated using an anti-Bcl-w antibody. Immunoprecipitates and total lysates (50 mg) were separated on 12%SDS polyacrilamide
gel and blotted with an anti-Akt antibody. As negative control, proteins were incubated with beads without antibody (B) Co-immunoprecipitation of
transfected Akt with FLAG-Bcl-w or EE-BAD. HEK-293 cells were tansfected with 2 mg of HA-Akt and 2 mg of FLAG-Bcl-w or EE-BAD cDNAs, as
indicated. After 48 hr, cells were lysed, and 1 mg of protein extract was immunoprecipitated using an anti-HA antibody. Immunoprecipitates were
subsequently blotted with anti-HA, anti-Flag or anti-EE antibodies, as indicated. (C) HEK-293 cells were transfected with 2 mg of either wt-Bcl-w cDNA
or the deletion mutants, Bcl-w/BH4 or Bcl-w/CT, as indicated. Protein extracts were immunoprecipitated using an anti-Akt antibody.
Immunoprecipitates and total lysates were resolved on 12%SDS-PAGE and transferred to Hybond-C nitrocellulose. Membranes were incubated
with an anti-FLAG antibody. Both deletion mutants, Bclw/BH4 and Bclw/CT, immunoprecipitated with Akt.
doi:10.1371/journal.pone.0004070.g001
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specific 20–25 nt siRNAs, or 150 nM anti-Bcl-w si-RNA (InVi-
trogen, Carlsbad, CA) with 6 ml transfection reagent, as described
in the manufacturer’s protocol.
Results
Akt interacts with Bcl-w
To find new interactors of Akt, we performed a yeast two-
hybrid screening with human full-length Akt c-DNA sequence as
bait and a murine c-DNA thyroid library as prey. Among the 100
clones obtained, two were identified as Bcl-w, covering its full
coding sequence. To confirm the interaction between Akt and Bcl-
w, we immunoprecipitated proteins from untreated, Akt-trans-
fected, and Bcl-w-transfected cells with an anti-Bcl-w antibody.
We found that Akt co-immunoprecipitates with Bcl-w in extracts
from untransfected and transfected cells (Figure 1A and 1B). The
extent of Akt binding with Bcl-w was comparable to that with its
substrate, Bad (Figure 1B).
Bcl-w contains four Bcl-2 homology (BH) domains and a
transmembrane (TM) fragment at the C-terminal region, impor-
tant for its insertion into the mitochondrial outer membrane. We
verified whether these regions are important for the interaction
with Akt. For this, HA-Akt cDNA was transfected together with
one of two Bcl-w domain-region cDNAs obtained by PCR and
fused to the FLAG epitope: these were the BH4 domain (45 aa) of
Bcl-w, located at the N-terminus, and the remaining portion of the
protein (97aa). Extracts were immunoprecipitated with an anti-
Flag antibody and blotted with an anti-HA antibody. We found
that Akt interacts with both Bcl-w deletion mutants, indicating that
Akt may interact with Bcl-w at multiple sites (Figure 1C).
Role of Akt activation on Akt/Bcl-w interaction
To find whether the activity of Akt influences its interaction
with Bcl-w, HeLa cells were transfected either with wild type Akt
(Akt wt) cDNA or with one of two mutants: an HA-tagged kinase
dead-Akt construct (Akt D2) with dominant negative functions,
and a constitutively active Akt construct (Akt D+). Protein extracts
were immunoprecipitated with a monoclonal anti-HA antibody
and then blotted with an anti-FLAG antibody. We found that Bcl-
w interacts with wild type Akt and more efficiently with the
activated kinase, but not with the kinase-dead Akt (Figure 2A).
Figure 2. Akt activity regulates Bcl-w expression. (A) HeLa cells were transfected with 2 mg of HA-Akt wt, Akt D+, or HA-Akt D2 cDNA and
2 mg Flag-Bcl-w for 48 hrs. Protein extracts were immunoprecipitated with an anti-HA monoclonal antibody. Immunoprecipitates were resolved on
12% SDS-PAGE and transferred to Hybond-C nitrocellulose. Membranes were incubated with anti-Flag antibody (0.2 mg/ml). 50 mg of total sample
extracts were also analyzed by western blot using the indicated antibodies. Loading control was obtained using anti-b actin antibody. (B) HeLa cells
were transfected with 4 mg of HA-Akt wt, HA-Akt D+, or HA-Akt D2 cDNA for 48 hrs. Protein extracts were blotted with anti-Bcl-w antibody in order
to detect endogenous levels of Bcl-w. Loading control was obtained with anti-b actin antibody. (C) Cells were transfected with 100 nM of siAkt-RNA
for 48 hrs. Cellular proteins were solubilized and analyzed by western blot using the indicated antibodies. (D) HeLa cells were treated with 10, 20 or
40 mM of LY294002 for 24 hrs. Protein extracts were analyzed by western blot using the indicated antibodies. Loading control was obtained using
anti-b actin antibody. (E) Bcl-w HeLa cells were treated with 10 mM of MG-132 for 8 hrs. 40 mg of protein extracts were analyzed by western blot with
anti-Bcl-w antibodies. Loading control was obtained using anti-b actin antibody.
doi:10.1371/journal.pone.0004070.g002
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When we transfected cells with Akt D2, we noticed a fall in the
expression of Bcl-w (Figure 2A). Therefore, lack of interaction
between Bcl-w and the kinase-dead Akt could have been due to
reduced expression of Bcl-w rather than to poor interaction with
Akt D2. To address this issue, we inhibited Akt in three different
ways: by interfering with its endogenous function; by treating cells
with Akt-siRNA; and by inhibiting the PI3K/Akt pathway with a
specific drug. In order to interfere with endogenous Akt activity,
we transfected cells with the previously described Akt mutant
cDNAs (Akt wt, Akt D+, and Akt D2). We found that Bcl-w was
reduced after transfection with inactive Akt, whereas Bcl-w
expression increased upon transfection with Akt D+ (Figure 2B).
In order to knock down endogenous Akt, HeLa cells were
transfected with a pool of Akt siRNAs. We found that endogenous
Akt expression, analyzed by Western blot, was reduced by .80%
after 48 hrs. This reduction in Akt expression was followed by a
drastic reduction in the level of Bcl-w. Moreover, the expression of
the anti-apoptotic protein, Bcl-2, but not of the pro-apoptotic
protein, Bax, was also reduced (Figure 2C). Finally, incubation of
HeLa cells with 10, 20 or 40 mM of LY294002, a specific inhibitor
of the PI3K pathway, resulted in reduced amount of Bcl-w protein
(Figure 2D). All these results provide evidence that the kinase
activity of Akt regulates the expression of Bcl-w.
To gain insight on the mechanism of Akt-mediated Bcl-w
regulation, we treated Bcl-w/HeLa cells with the proteasome
inhibitor, MG-132, for 8 hrs and then analyzed Bcl-w levels by
western blot (Figure 2E). The inhibition of the proteasome did not
result in an increase in Bcl-w expression, suggesting that the
ubiquitin pathway is not directly involved in the regulation of Bcl-
w by Akt.
Role of Akt in Bcl-w subcellular localization
Bcl-w is an anti-apoptotic protein weakly linked to the outer
mitochondrial membrane [21]. To verify its intracellular localiza-
tion, extracts of HeLa cells were fractionated to isolate
mitochondria from the cytosol. We found that Bcl-w is present
mainly in mitochondrial protein extracts (Figure 3A). To clarify
the role of Akt in determining Bcl-w cellular localization, HeLa
cells were transfected with Akt wt, Akt D+, or Akt D2 cDNAs
before fractional separation. We found that the presence of the
kinase-dead Akt mutant reduced the amount of Bcl-w linked to the
mitochondrial fraction and induced only a slight increase in the
cytosolic one (Figure 3B). Similar results were obtained in cells
transfected with Akt siRNA (Figure 3C). Thus, Akt acts mainly on
Bcl-w expression.
Akt phosphorylates Bcl-w
Akt is a serine threonine kinase that phosphorylates different
pro- and anti-apoptotic proteins. Thus, in vitro and in vivo
phosphorylation assays were performed to uncover whether Bcl-w
is a substrate of Akt. For in vitro assays, cells were transfected with
Flag-Bcl-w and the extracts obtained immunoprecipitated using a
monoclonal anti-Flag antibody. Immunoprecipitates were incu-
bated with a constitutively active Akt recombinant protein in the
presence of cP
32ATP. We found that Akt phosphorylates Bcl-w in
vitro, although not with the same efficiency as histone H2B
(Figure 4A).
To study the effects of Akt kinase activity on Bcl-w
phosphorylation in intact cells, we generated HeLa cells that
stably expressed Flag-Bcl-w (HeLa/Bcl-w). HeLa/Bcl-w cells were
stimulated with insulin or 10% serum for 15 min, and protein
extracts then immunoprecipitated using an anti-Flag antibody and
Figure 3. Akt controls Bcl-w localization. (A) HeLa cells were subjected to fractionated separation of mitochondrial/cytosolic proteins using a
mitochondria/cytosol fractionation kit (Biovision). Protein extracts were loaded onto 15% SDS polyacrilamide gel, and analyzed by western blot by
anti-Bcl-w antibody. As a control of the mitochondrial fraction, an anti-cox4 antibody was used. (B) HeLa cells were transfected with 2 mg of HA-Akt
WT, D+,o rD 2 for 48 hrs. Cells were subjected to mitochondria/cytosol separation as above. Protein extracts were analyzed by western blot using
anti-Bcl-w, anti-Akt, or anti-cox4 antibodies. (C) Cells were transfected with 100 nM of siAkt-RNA for 48 hrs. Cytosol and mitochondria were isolated
as described in the methods and analyzed by western blot using the indicated antibodies.
doi:10.1371/journal.pone.0004070.g003
AKT and Cell Death
PLoS ONE | www.plosone.org 5 December 2008 | Volume 3 | Issue 12 | e4070blotted with an anti-phospho (Ser/Thr) Akt substrate antibody
that recognizes the Akt substrate motif. We found that the
phosphorylated band corresponding to Bcl-w immunoprecipitates
upon stimulation with serum or insulin. These results taken
together provide evidence that Bcl-w may be a substrate of Akt
both in vitro and in intact cells (Figure 4B).
In turn, to investigate whether Bcl-w overexpression regulates
Akt kinase activity, HEK293 cells were co-transfected with Flag-
Bcl-w and HA-tagged Gsk3b, one of the main Akt substrates.
48 hours after transfection, the cells were stimulated with insulin
for 10 min, cellular extracts immunoprecipitated with an anti-HA
antibody, and then immunoblotted with an antibody that
recognizes the phosphorylated form of Gsk3b. We did not find a
change in the extent of Gsk3b phosphorylation by overexpressing
Bcl-w (Figure 4C). Therefore, Bcl-w binds to Akt and is a direct
substrate of Akt; however, this binding does not alter the activity of
Akt on other substrates.
Role of Bcl-w/Akt interaction on cell death
Given that Bcl-w is an anti-apoptotic member of the Bcl-2-
family, we investigated the role of Akt activity on this function. We
first analyzed the effect of Bcl-w overexpression in preventing
apoptosis induced by two different chemotherapics, i.e. cisplatin
and epirubicin, in HeLa/Bcl-w compared to parental untrans-
fected HeLa cells. Cells were treated with 30 mg/ml cisplatin or
with 10 mg/ml epirubicin for 24 hr. Cell death was assessed with a
cell viability assay, with propidium iodide staining followed by
FACS analysis, or by caspase 9, 23, and PARP activation. We
found that HeLa/Bcl-w cells were 80–90% resistant to cell death
induced by the chemotherapics. This was confirmed by analysis of
the activation state of the intrinsic apoptotic pathway (caspase 9,
23, and PARP) (Figure 5A).
To test the role of Akt activity on the antiapoptotic function of
Bcl-w, we repeated the above experiments in Bcl-w/HeLa cells
transfected for 48 hr either with Akt D2 cDNA or with Akt
siRNAs. We found that the inhibition of Akt kinase activity or
protein quantity resulted in a strong activation of the downstream
effector PARP (Figure 5 b, left panel), that is partially reflected as
reduction of pro-survival effect of Bcl-w (,20%) (Figure 5B). Thus,
Akt activity mediates the anti-apoptotic function at least in part by
regulating the intracellular levels of Bcl-w. Given that inhibiting
Akt results in a reduction of Bcl-w levels, these results suggest that
Akt may contribute to Bcl-w protective effects mainly by
regulating its intracellular levels.
To further confirm this, we down-regulated Bcl-w expression
with two specific Bcl-w-siRNAs, and analyzed the effects of Bcl-w
down-regulation on chemotherapy-induced cell death. We found
that 72 hrs of incubation with Bcl-w siRNAs drastically reduced
Bcl-w protein (Figure 6 A) although to different extents (siRNA61
was more effective than siRNA62). The assessment of cell viability
Figure 4. Akt phosphorylates Bcl-w in vitro and in vivo. (A) HeLa cells were transfected with 2 mg of DNA of Flag Bcl-w, solubilized, and 1 mg
of protein extract was immunoprecipitated with an anti-M2 Flag antibody. Immunoprecipitates were incubated with recombinant constitutive active
Akt (rAkt), and in vitro kinase assay was conducted as described in the methods. Samples were loaded onto 2.5% SDS-PAGE and analyzed by
autoradiography. As positive control we used Histone2B (H2B). (B) HeLa Bcl-w stable expressing clones were serum starved for 18 hrs and then
stimulated with 100 nM insulin or with 20% serum for 15 min as indicated. Cells were solubilized and immunoprecipitated with an anti-M2 Flag
antibody. Immunoprecipitates were loaded onto SDS-PAGE and blotted with an anti-phospho Akt substrate antibody that recognizes all the
phosphorylated Akt substrates. Total extracts were analyzed by western blot using the indicated antibodies. (C) HeLa cells were transfected with
2 mg of pcDNA3 empty vector or 2 mg of HA-GSK3b, and 2 mg of Flag-Bcl-w for 48 hrs. Cells were stimulated with 100 nM insulin for 15 min,
solubilized, immunoprecipitated using an anti-HA antibody, and analyzed by western blot using an anti-phospho-Gsk3 antibody. Total extracts were
analyzed by western blot using the indicated antibodies. Bcl-w overexpression does not affect Akt activity.
doi:10.1371/journal.pone.0004070.g004
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that the effect of cell death induced by chemotherapics was
proportional to the expression of Bcl-w. Furthermore, by reducing
Bcl-w level, we obtained the same ,20% increase in cell death
that we observed in HeLa cells treated with Akt siRNA. Thus, the
reduction in Bcl-w expression secondary to Akt inactivation
contributes to the resistance of cancer cells to chemotherapy-
induced cell death.
Akt regulates Bcl-w interaction with Bcl-2 family
members
The intrinsic apoptotic pathway is regulated by the net
interactions of pro- and anti-apoptotic Bcl-2 members [22]. To
evaluate the effect of Akt activity on the interaction of Bcl-w with
the pro-apoptotic Bcl-2 members, we set up co-immunoprecipi-
tation experiments with Bcl-w and Bad, Bik, or Bax in cells
overexpressing the dominant negative Akt cDNA. We found that
Akt inactivation resulted in a drastic reduction of Bcl-w interaction
with the pro-apoptotic proteins (Figure 7). This further confirms
the stimulatory role of Akt activity on Bcl-w anti-apoptotic
function.
Discussion
Apoptosis is believed to be the major mechanism of chemo-
therapy-induced cell death in cancer [23,24]. Unfortunately, many
tumour cells evade drug-induced death signals [25]. Akt is an
important survival-signaling molecule, whose function is frequent-
ly found altered in human cancer [5,26]. Therefore, we decided to
address the role of Akt in apoptosis resistance in human cancer by
finding new partners of Akt by two hybrid screening in yeast.
Among the interactors of Akt that we found, we focused on Bcl-w,
a pro-survival member of the Bcl-2 protein family [27,28] that has
received less attention compared to its other family members. By
genetic and biochemical methods, we have demonstrated here that
Akt interacts with the N- and C-terminal sequences of the Bcl-w
protein, and phosphorylates Bcl-w both in vitro and in the intact
cell. The analysis of the Bcl-w sequence did not reveal a canonical
Akt phosphorylation motif [29]. However, there is evidence that
Akt may phosphorylate cellular substrates at the level of a partially
conserved sequence motif [29]. Bcl-w posses at least 6 serine/
threonines that are included in ‘‘degenerated’’ Akt phosphoryla-
tion sites. By site-directed mutagenesis, we mutated two of these
sites (ser 62 and ser 83) substituting the serine with an alanine (data
Figure 5. Akt regulates the anti-apoptotic function of Bcl-w. (A) HeLa control cells and HeLa cells stably expressing Flag-Bcl-w were plated in
96 well plates in triplicate and treated with 30 mg/ml of cisplatin or 10 mg/ml of epirubicin for 24 hr. Apoptosis was analyzed by Cell Vitality assay, by
propidium iodide staining and FACS analysis, or by western blot for caspase cascade activation with anti-caspase-3, -9, and PARP antibodies. Loading
control was obtained with anti b-actin. (B) HeLa-Flag Bcl-w cells were transfected with 4 mg of HA-Akt D2 cDNA or with 100 nM of siAkt-RNA for
48 hrs and then treated with 30 mg/ml of cisplatin for 24 hr. Cell death was then analyzed as described above. Total lysates were analyzed by western
blot using an anti-PARP antibody. Loading control was obtained with an anti-b-actin antibody. Inactivation of Akt activity resulted in a reduction in
the protective effect of Bcl-w on cell death.
doi:10.1371/journal.pone.0004070.g005
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phosphorylation state, so the hypothetical Akt phosphorylation site
must be located elsewhere. We are now addressing this issue.
We have also demonstrated here that interfering with the
activity or amount of Akt reduces the quantity of Bcl-w protein;
oppositely, transfection of a dominant active Akt mutant increased
the content of Bcl-w in cells.
Akt-mediated Bcl-w down-regulation was observed to occur also
in glioma (data not shown). Thus, Akt affects Bcl-w function in
various cell types at least in part by regulating its expression. The
mechanisms underlying this are not clear, but the regulation of Bcl-
w protein levels is unlikely mediated by the ubiquitin-proteasome
pathway, as evidenced by the negative result obtained with a
proteasome inhibitor. Furthermore, Akt inhibition did not produce
an effect on Bcl-w mRNA, as evaluated by Real Time PCR (data
not shown).Other possible Akt-mediated regulatory effects on RNA
or protein stability are under investigation in our laboratory.
Several studies have suggested that Akt may regulate the
balance between pro- and anti-apoptotic signals, at least in part by
regulating the cellular localization of Bcl-2 family members
[30,31]. Thus, in this study we have analyzed the effect of Akt
activation on the subcellular localization of Bcl-w. We found Bcl-w
predominantly associated with the mitochondrial fraction, as
previously described also by O’Reilly et al. [32]. The presence of
the kinase-dead Akt mutant reduced the amount of Bcl-w linked to
this fraction, but it did not increase Bcl-w in the cytosol; we
obtained similar results with cells transfected with Akt siRNA.
Thus, via binding and phosphorylating Bcl-w, Akt may control
Bcl-w activity mainly through the regulation of Bcl-w protein
expression. We are conducting experiments with Bcl-w phosphor-
ylation mutants to formally prove this conclusion.
Moreover, with the intent to clarify the role of Akt-mediated
regulation of Bcl-w on its anti-apoptotic functions, we established a
Bcl-w overexpressing cell line. These cells exhibit a significant
decrease of chemotherapy-mediated cell death. When we
evaluated the effects of decreasing Akt activity on survival in
Bcl-w/HeLa cells, we found a ,20% increase in cell death.
However, when we analyzed cell death by western blot of PARP
activation, the active PARP fragment was present exclusively in
Bcl-w/HeLa cells incubated with Akt D2 cDNA. Thus, even
though the differences that we observe with FACS analysis and cell
vitality are of small entity, the end point, that is cell death
evaluated as PARP activation, is reached only in Bcl-w cells where
Akt has been inactivated.
Figure 6. Effects of Bcl-w si RNA on cell death. (A) Cells were transfected with 150 nM of siBcl-w-RNAs for 72 hrs. Total lysates were analyzed by
western blot using anti-Bcl-w antibodies. Loading control was obtained with an anti-b-actin antibody. (B, C) Cells were transfected with 150 nM of
siBcl-w-RNAs for 48 hrs. Then, the cells were splitted into 96 wells and then treated with 30 mg/ml of cisplatin for 24 hr. Cell death was then analyzed
with MTT (B) or propidium iodide staining and FACS analysis (C). Bcl-w down-regulation induces an increase of cell death.
doi:10.1371/journal.pone.0004070.g006
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the only defense mechanism of the cell toward chemotherapy-
induced apoptosis, and many other Bcl-2 family members may
mediate anti-apoptotic signals. Therefore, downregulation of Akt
may result in a pronounced efficacy in cancer cells were Bcl-w
predominates over the other Bcl-2 family members [33–35].
When appropriate stimuli are present, homodimerization of
pro-apoptotic members of the Bcl-2 family activates the intrinsic
apoptotic cascade. Bcl-w interacts with pro-apoptotic members of
the Bcl-2 family, such as Bad, Bax, and Bik, blocking the formation
of the homodimers and, thus, the activation of the apoptotic
cascade. Events that inhibit the formation of these Bcl-w/pro-
apoptotic Bcl-2 member complexes may lead to the activation of
apoptosis [36]. We show here that Bcl-w/Bax, Bcl-w/Bad, and
Bcl-w/Bik interactions were drastically reduced in cells overex-
pressing dominant-inactive Akt cDNA, indicating that Akt activity
is necessary for these interactions. Therefore, Akt may regulate the
anti-apoptotic function of Bcl-w, reducing its amount in the cell
and, thus, impairing the balance of homo- and heterodimer
formation upon apoptotic stimuli.
Bcl-w can be up-regulated in tumors such as gastric and
colorectal cancer [33–35]. Interestingly, the PI3k-Akt pathway is
involved in the progression and chemoresistance of these types of
cancer [37–39]. Therefore, increased Akt activity can be
speculated to promote survival and anti-apoptotic signaling in
cancer cells at least in part through increasing Bcl-w levels.
Recently, Bcl-w was reported to promote gastric cancer cell
invasion, by inducing matrix metalloproteinase-2 expression [34].
Bcl-w is up-regulated also through pathways besides the Akt one:
Tran et al. demonstrated that Bcl-w can be up-regulated via the
NFkB pathway activated by TWEAK (tumor necrosis factor-like
weak inducer of apoptosis) through stimulation of its receptor,
Fn14; moreover, the TWEAK-Fn14 pathway can induce survival
of glioma cells, at least in part by up-regulating the quantity of Bcl-
w protein [40]. In addition, Yao et al. reported that up-regulation
of Bcl-w protein mediates the neuroprotective effect of estrogens
[41]. Therefore, Bcl-w participates in a number of different
systems that regulate survival and anti-apoptotic pathways.
The results that we have presented here provide the first
evidence that Akt interacts with, and regulates the levels of, Bcl-w,
moving the balance of the Bcl-2 family toward anti-apoptotic
members. Enhancement of this Akt/Bcl-w anti-apoptotic pathway
can be speculated as one mechanism responsible for the reduced
sensitivity to apoptosis of cancer cells that are resistant to
chemotherapy-induced cell death. This finding may be of
importance in optimizing a strategy for the treatment of cancers,
such as gastric and colon adenocarcinoma, in which Bcl-w has
been found to be increased.
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